NCT03501173 - A Study of Participants With Advanced Prostate Cancer in Canada | Biotech Hunter

Enrollment

374

Participants

Timeline

Start Date

April 12, 2018

Primary Completion Date

July 14, 2023

Study Completion Date

July 14, 2023

Conditions

Prostatic Neoplasms

Interventions

OTHER

Standard of Care

Participants will not receive any intervention in this study. Participants will receive standard of care therapy.

Trial Locations (22)

T2N 4N2

Tom Baker Cancer Center, Calgary

T2V 1P9

Prostate Cancer Centre, Calgary

T6G 1Z2

University of Alberta, Edmonton

V2S 0C2

Abbotsford Regional Hospital and Cancer Centre BC Cancer Agency, Abbotsford

V1Y 5L3

British Columbia Cancer Agency(BCCA)-Sindi Ahluwalia Hawkins Centre for the Southern Interior(CSI), Kelowna

V5Z 1M9

Vancouver General Hospital / Vancouver Prostate Centre, Vancouver

V5Z 4E6

BC Cancer Agency - Vancouver BC, Vancouver

V8R 6V5

British Columbia Cancer Agency - Vancouver Island Centre, Victoria

R3E 0V9

Cancer Care Manitoba, Winnipeg

B3H 2Y9

Queen Elizabeth II - Health Sciences Centre, Halifax

L7N 3V2

G. Kenneth Jansz Medicine, Burlington

L8N 4A6

Research St. Joseph's - Hamilton, Hamilton

L8V 5C2

Hamilton Health Sciences Corporation, Hamilton

N6A 5W9

Lawson Health Research Institute, London

L5M 2V8

Credit Valley Hospital, Mississauga

K1H 8L6

The Ottawa Hospital Cancer Centre, Ottawa

M1VOE3

Scarborough Health Network, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

J4V 2H3

Urology South Shore Research, Greenfield Park

H2X 0A9

CHUM - Centre hospitalier universitaire de Montreal, Montreal

H3T 1E2

Jewish General Hospital, Montreal

G1R 2J6

CHU de Québec Université Laval, Québec

All Listed Sponsors

lead

Janssen Inc.

INDUSTRY